H.C. Wainwright Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Maintains Target Price $45
Cartesian Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $45 Price Target
H.C. Wainwright Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Maintains Target Price $45
Buy Rating on Cartesian Therapeutics: Advancing Cell Therapy With Innovative MRNA-Engineered CAR-T Treatments
Cartesian Therapeutics Analyst Ratings
Oppenheimer Sticks to Their Hold Rating for Cartesian Therapeutics (RNAC)
Buy Rating Affirmed for Cartesian Therapeutics Amid Clinical Success and Strengthened Financials
Cartesian Therapeutics Analyst Ratings
TD Cowen Initiates Cartesian Therapeutics(RNAC.US) With Buy Rating
Cartesian Therapeutics Analyst Ratings
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $42 Price Target
Canaccord Genuity Maintains Buy on Cartesian Therapeutics, Raises Price Target to $43
Buy Rating Affirmed for Cartesian Therapeutics on Descartes-08's Promising Clinical Trial Results
Cartesian Therapeutics Analyst Ratings
Optimistic Buy Rating for Cartesian Therapeutics Ahead of Phase IIb Trial Results
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $42 Price Target
Cartesian Therapeutics Analyst Ratings
Oppenheimer Reiterates Outperform on Cartesian Therapeutics, Maintains $50 Price Target
Cartesian Therapeutics Analyst Ratings